[{"id":"db802908-d352-4788-a1a5-ab4e959f4c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03009240","created_at":"2024-03-12T22:20:15.146Z","updated_at":"2024-07-02T16:35:15.595Z","phase":"Phase 1","brief_title":"Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia","source_id_and_acronym":"NCT03009240","lead_sponsor":"City of Hope Medical Center","biomarkers":" MIR155 • NFKB1","pipe":" | ","alterations":" miR-155 expression • NFKB1 expression","tags":["MIR155 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e miR-155 expression • NFKB1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/21/2017","start_date":" 08/21/2017","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-03-08"},{"id":"e4dc24bc-6ed7-4733-b143-e2d056f8bf8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05921812","created_at":"2023-06-27T14:08:25.821Z","updated_at":"2024-07-02T16:35:26.824Z","phase":"","brief_title":"Biochemical Role of Circulating microRNAs Expression as Diagnostic Markers for Non-Hodgkin's Lymphoma Patients","source_id_and_acronym":"NCT05921812","lead_sponsor":"Sohag University","biomarkers":" MIR155 • MIR21 • MIR16 • MIR16-1","pipe":"","alterations":" ","tags":["MIR155 • MIR21 • MIR16 • MIR16-1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-12-07"},{"id":"fe98e2d0-590c-4f9c-b62c-d6aca24eea9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015815","created_at":"2023-08-29T16:10:13.927Z","updated_at":"2024-07-02T16:35:38.717Z","phase":"","brief_title":"The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT","source_id_and_acronym":"NCT06015815","lead_sponsor":"Ankara University","biomarkers":" MIR155 • MIR21","pipe":" | ","alterations":" miR-155 expression","tags":["MIR155 • MIR21"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e miR-155 expression"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 10/05/2019","start_date":" 10/05/2019","primary_txt":" Primary completion: 04/29/2020","primary_completion_date":" 04/29/2020","study_txt":" Completion: 08/15/2020","study_completion_date":" 08/15/2020","last_update_posted":"2023-08-29"},{"id":"551a5d5c-0c4f-4b99-8dc4-682b204b8419","acronym":"","url":"https://clinicaltrials.gov/study/NCT05809050","created_at":"2023-04-12T14:03:11.796Z","updated_at":"2024-07-02T16:35:50.778Z","phase":"","brief_title":"Study of miRNA-155 in Acute Leukemia","source_id_and_acronym":"NCT05809050","lead_sponsor":"Sohag University","biomarkers":" MIR155","pipe":"","alterations":" ","tags":["MIR155"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-04-12"},{"id":"202a63d1-07ad-43e6-b0e5-90f62602468d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04149613","created_at":"2021-01-18T20:15:40.071Z","updated_at":"2024-07-02T16:36:07.094Z","phase":"","brief_title":"Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer","source_id_and_acronym":"NCT04149613","lead_sponsor":"American University of Beirut Medical Center","biomarkers":" MIR155 • MIR200B • MIR21 • MIR200C • MIR126 • MIR210 • MIR31 • CRP • MIR19A • MIR203A • MIR29A • MIR345","pipe":"","alterations":" ","tags":["MIR155 • MIR200B • MIR21 • MIR200C • MIR126 • MIR210 • MIR31 • CRP • MIR19A • MIR203A • MIR29A • MIR345"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 100","initiation":"Initiation: 05/25/2018","start_date":" 05/25/2018","primary_txt":" Primary completion: 12/18/2023","primary_completion_date":" 12/18/2023","study_txt":" Completion: 04/18/2024","study_completion_date":" 04/18/2024","last_update_posted":"2022-07-20"},{"id":"352af541-ad06-458d-a42d-d564efd06594","acronym":"","url":"https://clinicaltrials.gov/study/NCT03591367","created_at":"2021-01-18T17:39:49.258Z","updated_at":"2024-07-02T16:36:54.012Z","phase":"","brief_title":"The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation","source_id_and_acronym":"NCT03591367","lead_sponsor":"Mansoura University","biomarkers":" TERT • MIR155","pipe":"","alterations":" ","tags":["TERT • MIR155"],"overall_status":"Completed","enrollment":" Enrollment 115","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2019-11-04"}]